FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

5. Relationship of Reporting Person(s) to Issuer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

1. Name and Address of Reporting Person* Herberts Curt A. III (Victor) (Middle)					<u>S/</u>	2. Issuer Name and Ticker or Trading Symbol SANGAMO THERAPEUTICS, INC SGMO									ationship of Reporting all applicable) Director Officer (give title below)		g Person(s) to Issuer 10% Owner Other (speci below)		
(Last) (First) (Middle) C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CTR, 501 CANAL BLVD.				L	09	3. Date of Earliest Transaction (Month/Day/Year) 09/01/2017 4. If Amendment, Date of Original Filed (Month/Day/Year)									Sr.VP & Chief Business Officer 6. Individual or Joint/Group Filing (Check Applicable				
(Street) RICHMOND CA 94804					-									Form	·				
(City)	(S	tate)	(Zip)												_				
1. Title of Security (Instr. 3) 2. Tr			2. Trans	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Tran	, DIS	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			5. Amo Securit	unt of ies ially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) (D)	Price	Transa	Transaction(s) (Instr. 3 and 4)			(1130.4)	
Common Stock				09/0	/01/2017				S ⁽¹⁾		4,68	4 D	\$1	5 1	15,833		D		
Common Stock				09/0	01/2017				М		10,31	.6 A	\$5.	41 20	26,149		D		
Common Stock 09				09/0	01/2017				S ⁽¹⁾		10,31	.6 D	\$1	5 1	15,833		D		
											osed of, converti			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date I Expirati (Month/I	on Date		of Secur Underlyi Derivativ	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		xpiration ate	Title	Amoun or Numbe of Shares						
Stock Option (Right to Buy)	\$5.41	09/01/2017			M			10,316	(2)		12/05/2022	Common Stock	10,31	\$0.00	5,830)	D		

Explanation of Responses:

- 1. All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
- 2. The shares underlying the stock option are fully vested and exercisable.

Remarks:

/s/ Florence Tam, Attorney-in-09/01/2017 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.